Mylan launches Letrozole Tablets for hormone receptor-positive early stage breast can

[News]

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Letrozole Tablets USP, 2.5 mg, under a previously announced settlement and license agreement with Novartis. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Letrozole Tablets and will market the product with a period of exclusivity.

More... (http://www.news-medical.net/news/20110425/Mylan-launches-Letrozole-Tablets-for-hormone-receptor-positive-early-stage-breast-cancer.aspx)